2025-04-06 - Analysis Report
## Johnson & Johnson (JNJ) Stock Report

**0. Key Figures Summary:**

JNJ's cumulative return significantly lags behind the S&P 500 (VOO). While JNJ shows relatively stable revenue and profitability, recent performance has been weak, and its current valuation, relative to the market, presents a cautious outlook.  Further investigation into the drivers of recent underperformance is warranted.


**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a diversified healthcare company.

* **JNJ Cumulative Return:** 24.93%
* **S&P 500 (VOO) Cumulative Return:** 71.02%
* **Return Difference:** -46.1%  (Relative to historical range, this places JNJ at the 43.2nd percentile, indicating significant underperformance compared to the S&P 500.)

**Alpha and Beta Analysis:**

The provided data shows fluctuating alpha (excess return) and relatively stable beta (market sensitivity) over the years.  While alpha is positive in several periods, demonstrating outperformance, it's consistently below the market returns in recent years (2021-2025).  Beta remains close to 0.5, which aligns with its relatively stable nature in the market.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 29.0% | 56.0% | 0.0% | -0.0 | 275.3 |
| 2016-2018  | 9.0% | 10.8% | -8.0% | 0.1 | 261.2 |
| 2017-2019  | 19.0% | 10.8% | -10.0% | 0.7 | 303.6 |
| 2018-2020  | 15.0% | 10.8% | -14.0% | 0.5 | 336.4 |
| 2019-2021  | 33.0% | 7.9% | -41.0% | 0.4 | 374.9 |
| 2020-2022  | 10.0% | 59.9% | -10.0% | 0.3 | 397.3 |
| 2021-2023  | -22.0% | 60.6% | -50.0% | 0.5 | 363.2 |
| 2022-2024  | -36.0% | 60.6% | -52.0% | 0.4 | 345.7 |
| 2023-2025  | -4.0% | 79.7% | -7.0% | 0.3 | 369.3 |


**2. Recent Price Movement:**

* **Closing Price:** $153.24
* **Previous Close:** $159.82
* **Change:** -$4.12 (a notable decrease)
* **5-Day Moving Average:** $157.50
* **20-Day Moving Average:** $161.97
* **60-Day Moving Average:** $156.68

The price is below all three moving averages, suggesting a bearish trend.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4693 (High Risk)
* **RSI:** 36.84 (Approaching oversold territory, but not definitively so.)
* **PPO:** -0.81 (Negative, indicating bearish momentum.)
* **Relative Strength Change (20-day):** +14.0 (Short-term upward movement, but needs further confirmation).
* **Expected Return (vs. S&P 500, long-term):** -53.5% (Significant underperformance expected over the long term relative to the S&P 500).

The significant price drop (`change`: -$4.12) reflects a considerable negative market movement.  A further downward trend is possible.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue       |
|------------|-------|----------------|
| 2024-10-23 | $1.12 | $22.47B        |
| 2024-07-25 | $1.95 | $22.45B        |
| 2024-05-01 | $1.35 | $21.38B        |
| 2024-02-16 | $1.68 | $21.39B        |
| 2023-10-27 | $10.32 | $21.35B        |


EPS shows significant volatility.  The unusually high EPS in October 2023 requires further investigation to understand the underlying cause.  Revenue remains relatively stable.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $22.52B  | 68.35%        |
| 2024-09-30 | $22.47B  | 69.01%        |
| 2024-06-30 | $22.45B  | 69.40%        |
| 2024-03-31 | $21.38B  | 69.55%        |
| 2023-12-31 | $21.39B  | 68.23%        |

Revenue is relatively stable, and profit margins are high and consistent.


**Capital and Profitability:**

| Quarter | Equity    | ROE     |
|---------|-----------|---------|
| 2024-12-31 | $71.49B  | 4.80%   |
| 2024-09-30 | $70.16B  | 3.84%   |
| 2024-06-30 | $71.54B  | 6.55%   |
| 2024-03-31 | $70.02B  | 4.65%   |
| 2023-12-31 | $68.77B  | 5.89%   |

Equity and ROE show some fluctuation but remain relatively stable.


**6. Overall Analysis:**

JNJ exhibits strong financial fundamentals with consistent revenue and high profit margins.  However, the stock's recent performance lags significantly behind the S&P 500, indicated by a negative alpha and a substantial negative return difference. Technical indicators suggest a bearish trend, although the RSI is nearing oversold levels.  The extremely high EPS in Q4 2023 requires further investigation to determine its sustainability.  Given the current market conditions and long-term expected underperformance relative to the S&P 500, a cautious approach is advised.  Further research into the factors driving the recent underperformance is crucial before making any investment decisions.
